Author/Authors :
فرد اصفهاني، پژمان نويسنده Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran Fard-Esfahani, Pezhman , بيكي ، داوود نويسنده , , فلاحي، بابك نويسنده موسسه تحقيقات پزشكي هسته اي-بيمارستان دكتر شريعتي-دانشگاه علوم پزشكي تهران Fallahi, B. , فرد اصفهاني، ارمغان نويسنده دانشگاه علوم پزشكي تهران,مركز تحقيقات پزشكي هسته اي، بيمارستان دكتر شريعي , , امامي اردكاني، عليرضا نويسنده بيمارستان دكتر شريعتي Emami-Ardakani, Alireza , انصاري ، مجتبي نويسنده ansari, mojtaba , افتخاري ، محمد 1329 نويسنده پزشکي ,
Abstract :
Radioiodine therapy is the safest, simplest, least expensive and most effective method for treatment of
hyperthyroidism. The method employed in this research was a systematic bibliographic review, in which only
valid studies or the clinically detailed enough open-labeled studies using validated scales were used. Iodine-131
(I-131) acts by the destructive effect of short-range beta radiation on thyroid cells. Indications for radioiodine
therapy include toxic nodules (in which I-131 is the first choice of treatment), recurrent hyperthyroidism after
antithyroid treatment or surgery, intolerance to antithyroid therapy due to side-effects and patient preference.
Due to difficulties in previous methods for dose determination, fixed dose method of I-131 is now considered
the best practical method for radioiodine therapy in primary hyperthyroidism. Absolute contraindications for
radioiodine treatment are pregnancy and lactation. In pediatric patients, radioiodine therapy can be used, but is
mainly considered in recurrent toxic goiter and when antithyroid medication is ineffective. There is no clear
evidence indicative of carcinogenic or teratogenic effect of this agent.